Natural Heart Health Supplement Trial
Launched by EFFORIA, INC · Nov 1, 2024
Trial Information
Current as of June 17, 2025
Not yet recruiting
Keywords
ClinConnect Summary
We are conducting a 3-month study to see how a new natural heart health supplement can affect cholesterol levels and other heart-related health markers. Participants will take a daily dose of this chocolate-flavored supplement in powder form. We will measure changes in important heart health indicators, including total cholesterol, HDL (good cholesterol), LDL (bad cholesterol), triglycerides, and a protein that helps us understand inflammation in the body.
This trial is open to individuals aged 70 and older, and both men and women can participate. However, if you have a soy allergy, liver disease, or are pregnant or breastfeeding, you won't be eligible for this study. If you join, you can expect to take the supplement daily and help us learn more about how natural products can support heart health. Your participation could contribute valuable information that may help others in the future!
Gender
ALL
Eligibility criteria
- Exclusion Criteria:
- • Individuals with known soy allergies
- • Individuals with liver disease
- • Pregnant or breastfeeding individuals
About Efforia, Inc
Efforia, Inc. is a pioneering clinical trial sponsor dedicated to advancing innovative therapies in the healthcare sector. With a strong focus on precision medicine, Efforia leverages cutting-edge research and technology to design and conduct rigorous clinical trials aimed at addressing unmet medical needs. The organization collaborates closely with healthcare professionals, regulatory bodies, and industry partners to ensure the highest standards of safety and efficacy in its trials. Committed to improving patient outcomes, Efforia is at the forefront of transforming healthcare through its strategic approach to drug development and clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported